Asia Deal Watch: Astellas Looks To Next-Gen AAV Vectors Despite Gene Therapy Clinical Setbacks

Astellas inks agreement with Dyno Therapeutics for access to its CapsidMap platform for novel AAV vectors. Taiho takes option to Arcus TIGIT-targeted antibody candidates.

Asia Deal Watch

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker.

Astellas Pharma, Inc. and Dyno Therapeutics, Inc. announced on 2 December that they had signed an option and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deal Watch

More from Deals